new and emerging therapies in hcv

Introducing SeamlessCME™
INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM
Strategies for Safe and Efficacious Use of
2.0
A technology platform in which participants will utilize provided
iPads to log into the event, respond to assessment and evaluationn
questions, view all slides, and interact with the faculty.
NEW AND EMERGING
DAA
THERAPIES IN HCV
Monday, May 18, 2015
Marriott Marquis Washington, DC
Marquis Ballroom – Salon 6
Level 2
6:00 pm – 6:30 pm
Registration and Dinner
oral
HCV
G1
cirrhosis
tx-naï
aïve
interferon-
SVR
ACTIVITY CHAIR
Ira Jacobson, MD
HCV
SVR
FACULTY
Andrew Muir, MD, MHS
Nancy Reau, MD
Mark Sulkowski, MD
6:30 pm – 8:30 pm
CME-certified Activity
This continuing medical education activity is provided by
VINDICO
medical education
This activity is supported by an
educational grant from
Gilead Sciences Medical Affairs
®
This program is not affiliated with Digestive Disease Week .
REGISTER ONLINE!
VindicoCME.com/051815
DA
DAA
2015 © iStockphoto.com/Ballun; caracterdesign
OV
VERVIEW
W
DAA
DA
AA
Chronic hepaatitis C viru
us (HCV) infection iss a
leaading causse of cirrhoosis, end-sstage liverr disease,
hepatocellular carcinom
ma, and death from liver diseaase in the
United Statess. The disccovery, deevelopmennt, and availability
of direct-actiing antiviraal agents (DAAs) offfers new treeatment
opttions and the possibility of im
mproved outtcomes forr newly
diaagnosed paatients as well as thhose who have experiienced a
relapse or faailed to respond to previous tre
eatment. With the
approval of all-oral, intterferon-free combination therrapies
forr HCV treattment, heaalth care professionaals continuue to
be challengeed by severral clinica
al questions. In this CME
acttivity, strattegies for the safe and efficaciious use off HCV
theerapies, allong with thhe importtance of acchieving su
ustained
viral responsse for imprrovement of hepatic and extrahhepatic
maanifestations in mild as well as severe disease, wiill be
disscussed. The clinicall evidence
e regardingg optimal treatment
duration, moonitoring sttrategies, and drug--drug interaactions
forr interferonn-free regim
mens willl be review
wed, along with
theeir use in unique patiient populations.
LEARNING OBJECTIVES
Upon successful completion of this educational activity,
participants should be better able to:
•
Discuss the importance of HCV treatment and achievement
of sustained viral response for improvement of hepatic and
extrahepatic manifestations, in mild as well as severe disease.
•
Apply the clinical evidence to optimize treatment duration,
monitoring strategies and drug-drug interactions for newly
approved and emerging interferon-free regimens.
•
Appraise the clinical evidence to determine how to optimize
the use of newly approved and emerging interferon-free
regimens in special populations of patients including those
with decompensated cirrhosis, HIV/HCV coinfection, transplant/
post-transplant of liver, renal Impairment, and HCV genotype 3.
TARGET AUDIENCE
The intended audience for the activity is gastroenterologists,
hepatologists, nurse practitioner and physician assistant HCV
specialists, and other health care professionals involved in the
treatment of patients with HCV.
REGISTER ONLINE! VindicoCME.com/051815
Introducing SeamlessCME™
AGENDA
A technology platform in which participants will utilize
provided iPads to log into the event, respond to assessment
nt
and evaluation questions, view all slides, and interact with the faculty.
6:30 pm – 6:35 pm
Introduction and Pretest
Ira Jacobson, MD
6:35 pm – 6:55 pm
The Value Proposition of Achieving SVR:
Multifaceted Benefits & Managing
Resource Challenges
Nancy Reau, MD
6:55 pm – 7:20 pm
7:20 pm – 7:45 pm
Initial Treatment for a Patient with HCV
Genotype 1: Considerations for Interferon-Free
Treatment Regimens
Ira Jacobson, MD
Retreatment When Prior Therapy Has Failed
Andrew Muir, MD, MHS
7:45 pm – 8:05 pm
Key Points for the Use of New HCV Therapies
in Distinct Populations
Mark Sulkowski, MD
HCV
8:05 pm – 8:15 pm
Posttest
Ira Jacobson, MD
8:15 pm – 8:30 pm
Question and Answer
Moderated by Ira Jacobson, MD
Vindico Medical Education is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this live activity for a maximum of 2.0 AMA PRA
Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American
Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1
Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical
Education. Nurse practitioners can also apply for credit through their state boards.
American Academy of Physician Assistants (AAPA) accepts certificates of participation
for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations
accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours
credit for completing this program.
This educational activity is designed for AMA PRA Category 1 Credit(s)™ for US
physicians only. All non-US physicians should contact their respective Boards for
accreditation/credit status.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards
for Commercial Support, all planners, teachers, and authors involved in the development
of CME content are required to disclose to the accredited provider their relevant financial
relationships. Relevant financial relationships will be disclosed to the activity audience.
Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or
videotaping is prohibited without written permission from the program committee.
tx-naïve
REGISTER ONLINE!
VindiccoCM
ME.coom/00518115
SVR
ACTIVITY CHAIR
FACULTY
Ira Jacobson, MD
Andrew Muir, MD, MHS
Chairman, Department of Medicine
Mount Sinai Beth Israel Medical Center
Vice Chair of Medicine
Mount Sinai Health Care System
Senior Faculty, Icahn School of Medicine at Mount Sinai
New York, NY
Chief, Division of Gastroenterology
Director, GI/Hepatology Research Group
Associate Professor of Medicine
Department of Medicine
Duke University
Durham, NC
oral
HC
CV
Nancy Reau, MD
DAA
DA
A
G1
Associate Professor of Medicine
University of Chicago
Chicago, IL
cirrho
hosis
sis
tx-na
txnaïve
inte
in
nterfe
rferonfree
SVR
SV
R
Mark Sulkowski, MD
HCV
SV
VR
DAA
DA
A
Professor of Medicine
Medical Director of the Viral Hepatitis Center
Johns Hopkins School of Medicine
Baltimore, MD
REGISTER ONLINE! VindicoCME.com/051815
Monday, May 18, 2015
Marriott Marquis Washington, DC
Marquis Ballroom – Salon 6
Level 2
6:00 pm – 6:30 pm
Registration and Dinner
6:30 pm – 8:30 pm
CME-certified Activity
INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM
Strategies for Safe and Efficacious Use of
NEW AND EMERGING THERAPIES IN HCV
First Name ______________________________ M.I._______ Last Name _________________________________________
Preferred Mailing Address (Home/Business) ___________________________________________________________________
______________________________________________________________________________________________________
City___________________________
REGISTER ONLINE!
VindicoCME.com/051815
2.0
State_______ Zip Code ______________ Country ____________________________
Daytime Phone_______________________________________ Evening Phone ______________________________________
Fax ____________________________ E-mail ______________________________________ Date of Birth _______________
(for confirmation purposes)
(for confirmation purposes)
(for tracking credits ONLY)
National Provider Identifier (NPI)_______________ Medical License Number______________ Medical License State____________
Contact Information:
E-mail:
MeetingRegistration@VindicoCME.com
Toll-free: 877-307-5225, ext. 219 or 476
Phone:
856-994-9400, ext. 219 or 476
Fax:
856-251-0278
Mail:
Registration Department
6900 Grove Road
Thorofare, NJ 08086-9447
Priority Code: 678 - 1 2 3
Degree (please sppecify)
❑ MD/DO
❑ PhD
❑ MD, PhD
❑ PharmD/RPh
❑ PA
❑ RN/BSN/MSN
❑ NP
❑ Industry
❑ Other:_______
Ho
ow did you hear about this meetting?
(mu
ultiple selectio
ons allowed)
❑ Advertisement
❑ Brochure
❑ E-mail
❑ Postcard
❑ Web site
❑ Word of mouth
Spe
ecialtty (seelect onee)
❑
❑
❑
❑
Gastroenterology
Hepatology
Infectious Disease
Surgery
❑ Internal Medicine
❑ Family Practice/
General Practice
CM
ME Activvity Requ
uest
❑ YES, I would like to receive information regarding future
CME activities related to this therapeutic area.
ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons
with disabilities. Please call with your requests.
INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM
Strategies for Safe and Efficacious Use of
NEW AND EMERGING
THERAPIES IN HCV
Monday, May 18, 2015
Marriott Marquis Washington, DC
Marquis Ballroom – Salon 6
Level 2
6:00 pm – 6:30 pm
Registration and Dinner
6:30 pm – 8:30 pm
CME-certified Activity
REGISTER ONLINE!
VindicoCME.com/051815
2.0
VINDICO
medical education
6900 Grove Road • Building 100
Thorofare, NJ 08086-9447
Presorted
First Class Mail
US Postage
PAID
Permit # 906
Bellmawr NJ